21:52 , Jul 13, 2018 |  BioCentury  |  Strategy

Roche’s partnering priority

As James Sabry gets set to lead partnering for all of Roche pharma, his first order of business might be to build out the company’s late-stage pipeline ahead of an impending patent cliff that puts...
19:14 , Jul 13, 2018 |  BC Week In Review  |  Clinical News

Array reports Phase III OS data for encorafenib/binimetinib/Erbitux triple combo in mCRC

Array BioPharma Inc. (NASDAQ:ARRY) reported additional data from the safety lead-in portion of the open-label, international Phase III BEACON CRC trial showing that encorafenib (LGX818) plus binimetinib (MEK162) and Erbitux cetuximab led to a one-year...
03:05 , Jun 30, 2018 |  BioCentury  |  Finance

Hidden in the rough

Judicious stock picking was especially important in the second quarter, as 57% of global biotech stocks saw their equity values decline. Volatility continued to roil global markets during the period and additional uncertainty looms with the...
02:23 , Jun 30, 2018 |  BioCentury  |  Product Development

Defining access potential - before it’s too late

We see it everywhere: confirmation bias. Innovators believe in a drug, find the evidence to support its value, and dismiss or ignore the facts challenging their preferred story. But confirmation bias is particularly problematic thanks...
18:12 , Jun 29, 2018 |  BC Week In Review  |  Clinical News

FDA approves Array's drug combo to treat melanoma

Array BioPharma Inc. (NASDAQ:ARRY) said FDA approved Braftovi encorafenib in combination with Mektovi binimetinib to treat BRAF V600 mutation-positive unresectable or metastatic melanoma. The company said the combo is now available, but declined to provide...
22:04 , Jun 27, 2018 |  BC Extra  |  Company News

FDA approves Array's drug combo to treat melanoma

Array BioPharma Inc. (NASDAQ:ARRY) said FDA approved Braftovi encorafenib in combination with Mektovi binimetinib to treat BRAF V600 mutation-positive unresectable or metastatic melanoma. The company said the combo is now available, but declined to provide...
21:06 , Apr 6, 2018 |  BioCentury  |  Finance

Smid-cap smorgasbord

While the biggest milestone of the second quarter came early and turned out to be a disappointment, investors still have plenty to look forward to in immuno-oncology. In addition, specialist investors’ current strategy of overweighting...
23:15 , Mar 20, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: SNPs; Plasma markers A plasma cfDNA mutation on PI3KCA could help predict resistance to combined inhibition of MEK, CDK4 and CDK6 in NRAS-mutant melanoma. In samples from a patient with metastatic NRAS-mutant melanoma treated with...
16:17 , Feb 9, 2018 |  BC Week In Review  |  Clinical News

Array reports Phase III OS data for binimetinib plus encorafenib in melanoma

Array BioPharma Inc. (NASDAQ:ARRY) reported that binimetinib (MEK162) plus encorafenib (LGX818) significantly improved median overall survival (OS) compared to BRAF inhibitor Zelboraf vemurafenib in the Phase III COLUMBUS trial to treat BRAF V600 mutation-positive melanoma....
16:13 , Feb 9, 2018 |  BC Week In Review  |  Clinical News

Array reports Phase III OS data for binimetinib plus encorafenib in melanoma

Array BioPharma Inc. (NASDAQ:ARRY) reported that binimetinib (MEK162) plus encorafenib (LGX818) significantly improved median overall survival (OS) compared to BRAF inhibitor Zelboraf vemurafenib in the Phase III COLUMBUS trial to treat BRAF V600 mutation-positive melanoma....